• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection.

作者信息

Fiorcari Stefania, Atene Claudio Giacinto, Maffei Rossana, Debbia Giulia, Potenza Leonardo, Luppi Mario, Marasca Roberto

机构信息

Department of Medical and Surgical Sciences, Section of Hematology, University of Modena and Reggio Emilia, Modena, Italy.

Department of Medical and Surgical Sciences, Section of Hematology, University of Modena and Reggio Emilia, Modena, Italy; Hematology Unit, Department of Oncology and Hematology, A.O.U of Modena, Policlinico, Modena, Italy.

出版信息

Haematologica. 2021 Aug 1;106(8):2265-2268. doi: 10.3324/haematol.2020.277392.

DOI:10.3324/haematol.2020.277392
PMID:33691383
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8327720/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b81f/8327720/a809482efed0/1062265.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b81f/8327720/3be23d9220a5/1062265.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b81f/8327720/a809482efed0/1062265.fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b81f/8327720/3be23d9220a5/1062265.fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b81f/8327720/a809482efed0/1062265.fig2.jpg

相似文献

1
Ibrutinib interferes with innate immunity in chronic lymphocytic leukemia patients during COVID-19 infection.伊布替尼在新冠病毒感染期间干扰慢性淋巴细胞白血病患者的先天免疫。
Haematologica. 2021 Aug 1;106(8):2265-2268. doi: 10.3324/haematol.2020.277392.
2
Hepatitis B Virus Reactivation under Ibrutinib Treatment in a Patient with Chronic Lymphocytic Leukemia.依鲁替尼治疗慢性淋巴细胞白血病患者过程中出现的乙型肝炎病毒再激活
Turk J Haematol. 2020 Aug 28;37(3):208-209. doi: 10.4274/tjh.galenos.2020.2019.0180. Epub 2020 Apr 6.
3
Prognostic models in chronic lymphocytic leukemia patients receiving ibrutinib therapy: Results of a comparative performance analysis.接受依鲁替尼治疗的慢性淋巴细胞白血病患者的预后模型：比较性能分析结果
Eur J Haematol. 2021 Mar;106(3):425-427. doi: 10.1111/ejh.13548. Epub 2020 Nov 29.
4
Intracranial hemorrhage as presentation of chronic lymphocytic leukemia successfully treated with ibrutinib.以颅内出血为表现的慢性淋巴细胞白血病经依鲁替尼治疗成功
Ann Hematol. 2022 Jan;101(1):213-215. doi: 10.1007/s00277-021-04393-3. Epub 2021 Jan 9.
5
Using ibrutinib in earlier lines of treatment results in better outcomes for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.在慢性淋巴细胞白血病/小淋巴细胞淋巴瘤患者的早期治疗中使用依鲁替尼可产生更好的治疗效果。
Leuk Lymphoma. 2021 Dec;62(13):3278-3282. doi: 10.1080/10428194.2021.1957871. Epub 2021 Aug 13.
6
Ibrutinib-Induced Cardiac Tamponade in Chronic Lymphocytic Leukemia.依鲁替尼诱发慢性淋巴细胞白血病患者的心包填塞
Turk J Haematol. 2021 Feb 25;38(1):83-85. doi: 10.4274/tjh.galenos.2020.2020.0446. Epub 2020 Nov 9.
7
Natural history of noninfectious, ibrutinib-attributable adverse events in patients with chronic lymphocytic leukemia.慢性淋巴细胞白血病患者中与依鲁替尼相关的非感染性不良事件的自然病程
Leuk Lymphoma. 2021 Mar;62(3):716-721. doi: 10.1080/10428194.2020.1838508. Epub 2020 Nov 19.
8
Ibrutinib as initial therapy in chronic lymphocytic leukemia: A systematic review and meta-analysis.伊布替尼作为慢性淋巴细胞白血病的初始治疗：一项系统评价和荟萃分析。
Eur J Haematol. 2020 May;104(5):512-515. doi: 10.1111/ejh.13387. Epub 2020 Feb 22.
9
Adherence to ibrutinib remains an unmet clinical need in chronic lymphocytic leukemia.在慢性淋巴细胞白血病中，坚持使用依鲁替尼仍然是一项未满足的临床需求。
Leuk Lymphoma. 2022 Aug;63(8):1771-1773. doi: 10.1080/10428194.2022.2087072. Epub 2022 Jun 15.
10
Destabilization of ROR1 enhances activity of Ibrutinib against chronic lymphocytic leukemia in vivo.ROR1 失稳增强伊布替尼对体内慢性淋巴细胞白血病的活性。
Pharmacol Res. 2020 Jan;151:104512. doi: 10.1016/j.phrs.2019.104512. Epub 2019 Nov 12.

引用本文的文献

1
A case report of prolonged viral shedding of SARS-CoV-2 in a patient who receive ibrutinib for CLL therapy.CLL 治疗中接受伊布替尼治疗的患者 SARS-CoV-2 病毒持续排出的病例报告。
BMC Infect Dis. 2024 Sep 2;24(1):895. doi: 10.1186/s12879-024-09794-z.
2
Unexpected CD5 B Cell Lymphocytosis during SARS-CoV-2 Infection: Relevance for the Pathophysiology of Chronic Lymphocytic Leukemia.新型冠状病毒感染期间意外出现的CD5 B细胞淋巴细胞增多症：与慢性淋巴细胞白血病病理生理学的相关性
J Clin Med. 2023 Jan 28;12(3):998. doi: 10.3390/jcm12030998.
3
Recent clinical findings on the role of kinase inhibitors in COVID-19 management.

本文引用的文献

1
BTK Inhibition Impairs the Innate Response Against Fungal Infection in Patients With Chronic Lymphocytic Leukemia.BTK 抑制会损害慢性淋巴细胞白血病患者对真菌感染的固有免疫反应。
Front Immunol. 2020 Aug 28;11:2158. doi: 10.3389/fimmu.2020.02158. eCollection 2020.
2
COVID-19: more than a cytokine storm.新冠病毒肺炎：不止是一场细胞因子风暴
Crit Care. 2020 Sep 4;24(1):549. doi: 10.1186/s13054-020-03267-w.
3
Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study.
近期关于激酶抑制剂在 COVID-19 管理中作用的临床发现。
Life Sci. 2022 Oct 1;306:120809. doi: 10.1016/j.lfs.2022.120809. Epub 2022 Jul 13.
4
Underlying Ciliary Body Uveal Melanoma in a Patient with Chronic Lymphocytic Leukemia Presenting for Hyphema.一名患有慢性淋巴细胞白血病且因前房积血就诊的患者并发睫状体葡萄膜黑色素瘤。
Diagnostics (Basel). 2022 May 25;12(6):1312. doi: 10.3390/diagnostics12061312.
5
Clinical Trials of the BTK Inhibitors Ibrutinib and Acalabrutinib in Human Diseases Beyond B Cell Malignancies.布鲁顿酪氨酸激酶（BTK）抑制剂依鲁替尼和阿卡替尼在B细胞恶性肿瘤以外的人类疾病中的临床试验。
Front Oncol. 2021 Oct 28;11:737943. doi: 10.3389/fonc.2021.737943. eCollection 2021.
6
Multifaceted Immunomodulatory Effects of the BTK Inhibitors Ibrutinib and Acalabrutinib on Different Immune Cell Subsets - Beyond B Lymphocytes.布鲁顿酪氨酸激酶（BTK）抑制剂依鲁替尼和阿卡拉布替尼对不同免疫细胞亚群的多方面免疫调节作用——超越B淋巴细胞。
Front Cell Dev Biol. 2021 Aug 13;9:727531. doi: 10.3389/fcell.2021.727531. eCollection 2021.
意大利血液系统恶性肿瘤患者中与COVID-19严重程度相关的临床特征和危险因素：一项回顾性、多中心队列研究。
Lancet Haematol. 2020 Oct;7(10):e737-e745. doi: 10.1016/S2352-3026(20)30251-9. Epub 2020 Aug 13.
4
Outcomes of COVID-19 in patients with CLL: a multicenter international experience.慢性淋巴细胞白血病患者感染新型冠状病毒肺炎的结局：一项多中心国际经验
Blood. 2020 Sep 3;136(10):1134-1143. doi: 10.1182/blood.2020006965.
5
COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus.慢性淋巴细胞白血病患者的 COVID-19 严重程度和死亡率：ERIC、欧洲慢性淋巴细胞白血病研究倡议和 CLL 校园的联合研究。
Leukemia. 2020 Sep;34(9):2354-2363. doi: 10.1038/s41375-020-0959-x. Epub 2020 Jul 9.
6
Inhibition of Bruton tyrosine kinase in patients with severe COVID-19.在重症 COVID-19 患者中抑制布鲁顿酪氨酸激酶。
Sci Immunol. 2020 Jun 5;5(48). doi: 10.1126/sciimmunol.abd0110.
7
Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19.布鲁顿酪氨酸激酶抑制剂在慢性淋巴细胞白血病合并新型冠状病毒肺炎患者中的保护作用
Br J Haematol. 2020 Jul;190(2):e73-e76. doi: 10.1111/bjh.16863. Epub 2020 Jun 4.
8
BTK Inhibitors in Cancer Patients with COVID-19: "The Winner Will be the One Who Controls That Chaos" (Napoleon Bonaparte).在感染 COVID-19 的癌症患者中使用 BTK 抑制剂：“胜者将是那个能控制住混乱局面的人”（拿破仑·波拿巴）。
Clin Cancer Res. 2020 Jul 15;26(14):3514-3516. doi: 10.1158/1078-0432.CCR-20-1427. Epub 2020 Apr 28.
9
The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients.布鲁顿酪氨酸激酶（BTK）抑制剂依鲁替尼可能对新冠病毒感染患者的肺损伤具有保护作用。
Blood. 2020 May 21;135(21):1912-1915. doi: 10.1182/blood.2020006288.
10
A pneumonia outbreak associated with a new coronavirus of probable bat origin.一种新型冠状病毒引发的肺炎疫情，该病毒可能来源于蝙蝠。
Nature. 2020 Mar;579(7798):270-273. doi: 10.1038/s41586-020-2012-7. Epub 2020 Feb 3.